A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

NCT03663114 · clinicaltrials.gov ↗

COMPLETED

Status

713

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Inc.